Prognostic Value of Soluble Programmed Cell Death Ligand-1 (sPD-L1) in Various Cancers: A Meta-analysis
AbstractBackgroundThe prognostic value of soluble programmed cell death ligand-1 (sPD-L1) in patients with cancer has been inconsistent across previous studies.ObjectiveThis meta-analysis aimed to investigate the prognostic significance of sPD-L1 in human tumors.MethodsA comprehensive search of PubMed, Web of Science, Embase, and Cochrane databases from inception to January 6, 2020 was conducted. Studies of sPD-L1 measured by enzyme-linked immunosorbent assay (ELISA) that had available hazard ratios (HRs) for survival outcomes based on high or low sPD-L1 levels were included. The primary endpoint was long-term survival, na...
Source: Targeted Oncology - November 22, 2020 Category: Cancer & Oncology Source Type: research

Selective Oral MEK1/2 Inhibitor Pimasertib in Metastatic Melanoma: Antitumor Activity in a Phase I, Dose-Escalation Trial
ConclusionResults from this phase I study indicate that pimasertib has clinical activity in patients with locally advanced/metastatic melanoma, particularlyBRAF- andNRAS-mutated tumors, at clinically relevant doses associated with pERK inhibition in peripheral blood mononuclear cells.Trial RegistrationClinicalTrials.gov, NCT00982865 (Source: Targeted Oncology)
Source: Targeted Oncology - November 19, 2020 Category: Cancer & Oncology Source Type: research

Impact of Dose Reduction on Efficacy: Implications of Exposure-Response Analysis of Palbociclib
ConclusionsThis analysis suggests that palbociclib exposure has no impact on PFS when the dose reduction algorithm from palbociclib clinical trials is used. There is no difference in efficacy between Asians and non-Asians, despite the higher level of dose reductions in Asians.PfizerNCT01740427. (Source: Targeted Oncology)
Source: Targeted Oncology - November 19, 2020 Category: Cancer & Oncology Source Type: research

SB8: A Bevacizumab Biosimilar
AbstractSB8 is a biosimilar of the monoclonal anti-VEGF antibody bevacizumab and is approved in the EU for use in the same types of cancer as bevacizumab. SB8 has similar physicochemical and pharmacodynamic properties to those of reference bevacizumab and pharmacokinetic equivalence was shown in healthy volunteers and patients with non-small cell lung cancer (NSCLC). SB8 demonstrated equivalent clinical efficacy to reference bevacizumab in patients with metastatic or recurrent nonsquamous NSCLC, with similar tolerability, safety and immunogenicity profiles. (Source: Targeted Oncology)
Source: Targeted Oncology - November 18, 2020 Category: Cancer & Oncology Source Type: research

Acknowledgement to Referees
(Source: Targeted Oncology)
Source: Targeted Oncology - November 17, 2020 Category: Cancer & Oncology Source Type: research

Correction to: Efficacy and Safety of ABP 798: Results from the JASMINE Trial in Patients with Follicular Lymphoma in Comparison with Rituximab Reference Product
Discussion, right column, second paragraph. (Source: Targeted Oncology)
Source: Targeted Oncology - November 12, 2020 Category: Cancer & Oncology Source Type: research

Selective Oral MEK1/2 Inhibitor Pimasertib: A Phase I Trial in Patients with Advanced Solid Tumors
ConclusionsBased on the safety profile and efficacy signals, a continuous bid regimen was the preferred dosing schedule and the RP2D was defined as 60 mg bid.Trial RegistrationClinicalTrials.gov, NCT00982865. (Source: Targeted Oncology)
Source: Targeted Oncology - November 10, 2020 Category: Cancer & Oncology Source Type: research

Correction to: Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE ‑2 Study
The listing of the author names and affiliations, which previously read. (Source: Targeted Oncology)
Source: Targeted Oncology - November 10, 2020 Category: Cancer & Oncology Source Type: research

Developing Symptom Lists for People with Cancer Treated with Targeted Therapies
ConclusionsSymptom lists should be created based on input from patients. The item set described will be applicable to the assessment of new TTs, and in monitoring treatment. (Source: Targeted Oncology)
Source: Targeted Oncology - November 9, 2020 Category: Cancer & Oncology Source Type: research

Everolimus in Advanced Breast Cancer: A Systematic Review and Meta-analysis
ConclusionsEverolimus reduces the risk of disease progression in hormone receptor (+) MBC. In patients with HER2 (+) disease, the benefit is limited for those with hormone receptor ( −) disease. Given the approval and use of newer drugs in MBC, clinical trials and real-world data are needed to confirm the benefit of everolimus and define the best treatment sequence strategy to adopt in that setting. (Source: Targeted Oncology)
Source: Targeted Oncology - November 5, 2020 Category: Cancer & Oncology Source Type: research

A Melanoma-Tailored Next-Generation Sequencing Panel Coupled with a Comprehensive Analysis to Improve Routine Melanoma Genotyping
ConclusionsOur tailored next-generation sequencing assay coupled with a comprehensive analysis may improve therapeutic management in a significant number of patients with melanoma. Updating such a panel and implementing multi-omic approaches will further enhance patients ’ clinical management. (Source: Targeted Oncology)
Source: Targeted Oncology - November 5, 2020 Category: Cancer & Oncology Source Type: research

Correction to: Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma
An Online First version of this article was made available online athttps://link.springer.com/article/10.1007/s11523-020-00757-3 on 12 October 2020. Errors were subsequently identified in the article, and the following corrections should be noted. (Source: Targeted Oncology)
Source: Targeted Oncology - October 28, 2020 Category: Cancer & Oncology Source Type: research

Correction to: Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer
The article Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer (Source: Targeted Oncology)
Source: Targeted Oncology - October 27, 2020 Category: Cancer & Oncology Source Type: research

Cetuximab in Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Ovarian Cancer Without KRAS, NRAS, or BRAF Mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study
ConclusionsCetuximab does not have clinical activity in patients with advanced BC, NSCLC, and OC withoutKRAS, NRAS, or BRAF mutations.Clinical Trial RegistrationNCT02693535 (26 February, 2016). (Source: Targeted Oncology)
Source: Targeted Oncology - October 22, 2020 Category: Cancer & Oncology Source Type: research

Correction to: Biologic Drug Quality Assurance to Optimize HER2+  Breast Cancer Treatment: Insights from Development of the Trastuzumab Biosimilar SB3
The article Biologic Drug Quality Assurance to Optimize HER2+  Breast Cancer Treatment: Insights from Development of the Trastuzumab Biosimilar SB3, (Source: Targeted Oncology)
Source: Targeted Oncology - October 20, 2020 Category: Cancer & Oncology Source Type: research

Targeting Nuclear Export Proteins in Multiple Myeloma Therapy
AbstractMultiple myeloma (MM) is an incurable malignancy of plasma cells with a clinical course characterized by multiple relapses and treatment refractoriness. While recent treatment advancements have extended overall survival (OS), refractory MM has a poor prognosis, with a median OS of between 4 and 6 months. Nuclear export inhibition, specifically inhibition of CRM1/XPO1, is an emerging novel treatment modality that has shown promise in treatment-refractory MM. Initially discovered in yeast in 1983, early clinical applications were met with significant toxicities that limited their utility. The creation of small molecu...
Source: Targeted Oncology - October 19, 2020 Category: Cancer & Oncology Source Type: research

Rechallenge with Anti-EGFR Therapy in Metastatic Colorectal Cancer (mCRC): Results from South Australia mCRC Registry
ConclusionsAnti-EGFR rechallenge provides clinical benefit in patients withRAS wild-type metastatic CRC. (Source: Targeted Oncology)
Source: Targeted Oncology - October 17, 2020 Category: Cancer & Oncology Source Type: research

Sunitinib in Patients with Metastatic Colorectal Cancer (mCRC) with FLT - 3 Amplification: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study
ConclusionsMonotherapy with sunitinib does not have clinical activity in patients with mCRC withFLT-3 amplification and should not be prescribed for off-label use. Other treatments should be considered for these patients, including treatments offered in clinical trials.Clinical Trial registrationNCT02693535 (26 February 2016). (Source: Targeted Oncology)
Source: Targeted Oncology - October 17, 2020 Category: Cancer & Oncology Source Type: research

Poly(ADP-Ribose) Polymerase Inhibitors in Prostate Cancer: Molecular Mechanisms, and Preclinical and Clinical Data
AbstractGenomic instability is one of the hallmarks of cancer. The incidence of genetic alterations in homologous recombination repair genes increases during cancer progression, and 20% of prostate cancers (PCas) have defects in DNA repair genes. Several somatic and germline gene alterations drive prostate cancer tumorigenesis, and the most important of these areBRCA2,BRCA1,ATM andCHEK2. There is a group of BRCAness tumours that share phenotypic and genotypic properties with classicalBRCA-mutated tumours. Poly(ADP-ribose) polymerase inhibitors (PARPis) show synthetic lethality in cancer cells with impaired homologous recom...
Source: Targeted Oncology - October 12, 2020 Category: Cancer & Oncology Source Type: research

Efficacy and Safety of ABP 798: Results from the JASMINE Trial in Patients with Follicular Lymphoma in Comparison with Rituximab Reference Product
ConclusionsThese results support a conclusion of similar clinical efficacy between ABP 798 and rituximab RP in patients with follicular lymphoma.NCT NumberNCT02747043; first posted April 21, 2016.EudraCT Number2013-005,542-11; submitted 14 October, 2014. (Source: Targeted Oncology)
Source: Targeted Oncology - October 12, 2020 Category: Cancer & Oncology Source Type: research

Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma
The objective of this study was to analyse the prognostic role of the baseline eosinophil count in patients with sorafenib-treated hepatocellular carcinoma.Patients and MethodsA training cohort of 92 patients with advanced- or intermediate-stage sorafenib-treated hepatocellular carcinoma and two validation cohorts of 65 and 180 patients were analysed. Overall survival and progression-free survival in relation to baseline eosinophil counts were estimated by the Kaplan –Meier method. Univariate and multivariate analyses were performed.ResultsA negative prognostic impact of low baseline eosinophil counts (
Source: Targeted Oncology - October 12, 2020 Category: Cancer & Oncology Source Type: research

Efficacy, Prognostic Factors, and Safety Profile of Enzalutamide for Non-metastatic and Metastatic Castration-Resistant Prostate Cancer: A Retrospective Single-Center Analysis in Japan
AbstractBackgroundEnzalutamide is a novel, non-steroidal anti-androgen that has demonstrated excellent anti-tumor activity for both non-metastatic and metastatic castration-resistant prostate cancer (nmCRPC and mCRPC) patients, and that is being rapidly introduced into clinical practice in Japan.ObjectiveWe retrospectively investigated the treatment efficacy, safety profile, and prognostic factors of enzalutamide over a relatively long observation period in Japanese patients with nmCRPC and mCRPC.Patients and methodsThe medical records of 184 consecutive Japanese patients with nmCRPC and mCRPC who started enzalutamide trea...
Source: Targeted Oncology - October 10, 2020 Category: Cancer & Oncology Source Type: research

Small Molecule Destabilizer of β-Catenin and Ras Proteins Antagonizes Growth of K-Ras Mutation-Driven Colorectal Cancers Resistant to EGFR Inhibitors
ConclusionsCPD0857 may be a potential drug for treating aggressive CRC carrying mutations that aberrantly activate Wnt/ β-catenin and Ras-ERK pathways. (Source: Targeted Oncology)
Source: Targeted Oncology - October 6, 2020 Category: Cancer & Oncology Source Type: research

Phase II Trial of Palbociclib in Recurrent Retinoblastoma-Positive Anaplastic Oligodendroglioma: A Study from the Spanish Group for Research in Neuro-Oncology (GEINO)
ConclusionDespite the good tolerance, palbociclib monotherapy did not show favorable efficacy against recurrent AO.Trial RegistrationThis study is registered with ClinicalTrials.gov, identifier NCT0253032 (retrospectively registered on 21 August 2015). (Source: Targeted Oncology)
Source: Targeted Oncology - October 5, 2020 Category: Cancer & Oncology Source Type: research

Targeting TAM to Tame Pancreatic Cancer
AbstractPancreatic cancer is expected to become the second leading cause of cancer-related death within the next few years. Current therapeutic strategies have limited effectiveness and therefore there is an urgency to develop novel effective therapies. The receptor tyrosine kinase subfamily TAM (Tyro3, Axl, MerTK) is directly implicated in the pathogenesis of the metastatic, chemoresistant, and immunosuppressive phenotype in pancreatic cancer. TAM inhibitors are promising investigational therapies for pancreatic cancer due to their potential to target multiple aspects of pancreatic cancer biology. Specifically, recent mec...
Source: Targeted Oncology - September 28, 2020 Category: Cancer & Oncology Source Type: research

Early Tumor Shrinkage and Depth of Response in the Second-Line Treatment for KRAS exon2 Wild-Type Metastatic Colorectal Cancer: An Exploratory Analysis of the Randomized Phase 2 Trial Comparing Panitumumab and Bevacizumab in Combination with FOLFIRI (WJOG6210G)
AbstractBackgroundPredictive markers for the clinical outcomes of second-line treatment in patients with metastatic colorectal cancer (mCRC) remain unclear.ObjectiveThis retrospective biomarker study was conducted to explore predictive markers for patients withKRAS exon 2 wild-type mCRC who were treated with FOLFIRI plus panitumumab (Pani) or bevacizumab (Bev) in the WJOG6210G trial.Patients and methodsThe associations of early tumor shrinkage (ETS), tumor location, and VEGF-D with progression-free survival (PFS) and overall survival (OS) were analyzed using a Cox proportional hazards model. Spearman ’s correlation c...
Source: Targeted Oncology - September 21, 2020 Category: Cancer & Oncology Source Type: research

Gilteritinib: A Review in Relapsed or Refractory FLT3 -Mutated Acute Myeloid Leukaemia
AbstractGilteritinib (Xospata®), a next-generation tyrosine kinase inhibitor (TKI), is approved in several countries/regions worldwide for the treatment of relapsed or refractory acute myeloid leukaemia (AML) in adults with FMS-like tyrosine kinase 3 (FLT3) mutations. In this patient population, oral gilteritinib significantly improved overall survival (OS) and the response rate for complete remission with full or partial haematological recovery compared with salvage chemotherapy in the phase III ADMIRAL trial. In an integrated safety analysis of patients with relapsed or refractory AML, the most commonly reported grad...
Source: Targeted Oncology - September 16, 2020 Category: Cancer & Oncology Source Type: research

Applying Precision to the Management of BRAF-Mutant Metastatic Colorectal Cancer
AbstractIdentifying the presence or absence of aBRAFV600E mutation is paramount for the management of patients with metastatic colorectal cancer (mCRC) as there are distinct predictive and prognostic implications, as well as unique therapeutic approaches for this molecular subtype. Traditional cytotoxic doublet chemotherapy has historically been ineffective for this poor prognostic group, thereby highlighting the critical need for novel targeted therapies to drive management. Unlike the early success achieved with BRAF-inhibitor monotherapy for patients withBRAFV600E-mutated metastatic melanoma, response rates were found t...
Source: Targeted Oncology - September 4, 2020 Category: Cancer & Oncology Source Type: research

Efficacy and Safety of Crizotinib in the Treatment of Advanced Non-Small-Cell Lung Cancer with ROS1 Rearrangement or MET Alteration: A Systematic Review and Meta-Analysis
ConclusionOur study highlighted and confirmed the efficacy of crizotinib in patients with NSCLC withROS1 orMET genetic alterations. Crizotinib had remarkable effects on advanced NSCLC withROS1 fusion, as previously reported. However, the role of this targeted therapy inMET-altered NSCLC remains investigational. (Source: Targeted Oncology)
Source: Targeted Oncology - August 30, 2020 Category: Cancer & Oncology Source Type: research

Correction to: Cabozantinib After a Previous Immune Checkpoint Inhibitor in Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional Analysis
While typesetting the article the Table 3 column/row entries are interchanged. Please find below the updated Table (Source: Targeted Oncology)
Source: Targeted Oncology - August 27, 2020 Category: Cancer & Oncology Source Type: research

In Vitro Comparison of the Effects of Imatinib and Ponatinib on Chronic Myeloid Leukemia Progenitor/Stem Cell Features
ConclusionPonatinib seems to target CML progenitor/stem cells better than imatinib. (Source: Targeted Oncology)
Source: Targeted Oncology - August 10, 2020 Category: Cancer & Oncology Source Type: research

Comparison of Large, Medium, and Small Solid Tumor Gene Panels for Detection of Clinically Actionable Mutations in Cancer
ConclusionsThe results demonstrate that a carefully designed medium size gene panel is as effective as a large panel for the detection of clinically actionable variants and can be run by most molecular pathology laboratories. (Source: Targeted Oncology)
Source: Targeted Oncology - August 7, 2020 Category: Cancer & Oncology Source Type: research

Management of Adverse Events Associated with Cabozantinib Treatment in Patients with Advanced Hepatocellular Carcinoma
AbstractCabozantinib is an oral multikinase inhibitor whose targets include vascular endothelial growth factor receptors, MET, and the TAM family of kinases (TYRO3, AXL, MER). Cabozantinib is approved for patients with advanced hepatocellular carcinoma who have been previously treated with sorafenib, based on improved overall survival and progression-free survival relative to placebo in the phase III CELESTIAL study. During CELESTIAL, the most common adverse events (AEs) experienced by patients receiving cabozantinib included palmar-plantar erythrodysesthesia, fatigue, gastrointestinal-related events, and hypertension. The...
Source: Targeted Oncology - August 7, 2020 Category: Cancer & Oncology Source Type: research

Biologic Drug Quality Assurance to Optimize HER2  + Breast Cancer Treatment: Insights from Development of the Trastuzumab Biosimilar SB3
AbstractSB3 is a biosimilar of trastuzumab that has been approved for use in the treatment of human epidermal growth factor 2-positive breast cancer and human epidermal growth factor 2-positive gastric cancer. Antibody-dependent cellular cytotoxicity is one of several critical quality attributes of trastuzumab. Data from the development of SB3 support the hypothesis of a relationship between antibody-dependent cellular cytotoxicity activity and clinical outcomes in terms of the response rate and long-term survival. Current analytic methods utilizing advanced technology allow the detection of small changes in other quality ...
Source: Targeted Oncology - August 2, 2020 Category: Cancer & Oncology Source Type: research

Sarcopenia in Metastatic Renal Cell Carcinoma Patients Treated with Cabozantinib
ConclusionsSignificant and early skeletal muscle loss occurs during treatment with cabozantinib in a high proportion of patients and is associated with poor PFS. (Source: Targeted Oncology)
Source: Targeted Oncology - August 2, 2020 Category: Cancer & Oncology Source Type: research

Antibody –Drug Conjugates in Thoracic Malignancies: Clinical Trials Reveal Both Promise and Challenges
AbstractThoracic malignancies are the main cause of cancer-related deaths worldwide. The need to develop new therapies is therefore urgent. The recognition of new potential therapeutic targets in thoracic malignancies has prompted the development of a number of antibody –drug conjugates. This new class of potent anticancer agents is supposed to more specifically and directly target the tumor while limiting toxicity for healthy tissues by delivering a toxic payload to tumor cells that are recognized by the presence of specific cell surface antigens. Progress in th e development of antibody–drug conjugates over t...
Source: Targeted Oncology - July 27, 2020 Category: Cancer & Oncology Source Type: research

Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from Pharmacovigilance
AbstractThe advent of immune checkpoint inhibitors (ICIs) caused a paradigm shift both in drug development and clinical practice; however, by virtue of their mechanism of action, the excessively activated immune system results in a multitude of off-target toxicities, the so-called immune-related adverse events (irAEs), requiring new skills for timely diagnosis and a multidisciplinary approach to successfully manage the patients. In the recent past, a plethora of large-scale pharmacovigilance analyses have characterized various irAEs in terms of spectrum and clinical features in the real world. This review aims to summarize...
Source: Targeted Oncology - July 27, 2020 Category: Cancer & Oncology Source Type: research

Untangling the Multidisciplinary Care Web: Streamlining Care Through an Immune-Related Adverse Events (IRAE) Tumor Board
AbstractImmune-related adverse events (IRAEs) are becoming increasingly common as the use of immune checkpoint inhibitors expands into more tumor types and treatment settings. Although the majority of IRAEs are mild and can be managed in the outpatient setting by the medical oncologist, severe IRAEs can be life threatening and often require complex care coordination among multiple providers. These providers include a variety of non-oncology specialists who have interest and expertise in managing IRAEs. Multiple systems-based solutions have been proposed in the literature, but these need to be tailored to the needs and reso...
Source: Targeted Oncology - July 23, 2020 Category: Cancer & Oncology Source Type: research

Post-Progression Survival in Secondary EGFR T790M-Mutated Non-Small-Cell Lung Cancer Patients With and Without Osimertinib After Failure of a Previous EGFR TKI
AbstractBackgroundOsimertinib is effective in non-small-cell lung cancer (NSCLC) with an acquired epidermal growth factor receptor (EGFR) T790M mutation, the most common resistance mechanism to first- and second-generation EGFR tyrosine kinase inhibitors (TKIs).ObjectivesWe aimed to evaluate survival outcome of patients with EGFR-mutant NSCLC who have progressed on previous EGFR TKI therapy.Patients and MethodsAdvanced NSCLC patients with EGFR mutation after acquired resistance to first- or second-generation EGFR TKI who received tumor rebiopsy after EGFR TKI failure from 1 January 2012 to 31 December 2017 were reviewed. P...
Source: Targeted Oncology - July 20, 2020 Category: Cancer & Oncology Source Type: research

Cabozantinib After a Previous Immune Checkpoint Inhibitor in Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional Analysis
AbstractBackgroundAngiogenesis has been recognized as the most important factor for tumor invasion, proliferation, and progression in metastatic renal cell carcinoma (mRCC). However, few clinical data are available regarding the efficacy of cabozantinib following immunotherapy.ObjectiveTo describe the outcome of cabozantinib in patients previously treated with immunotherapy.Patients and methodsPatients with mRCC who received cabozantinib immediately after nivolumab were included. The primary endpoint was to assess the outcome in terms of efficacy and activity.ResultsEighty-four mRCC patients met the criteria to be included...
Source: Targeted Oncology - July 14, 2020 Category: Cancer & Oncology Source Type: research

Ceritinib-Induced Organizing Pneumonia in Lung Cancer: A Retrospective Analysis
AbstractBackgroundCeritinib is a potent selective ALK inhibitor with a manageable safety profile. In anecdotal reports, ceritinib was associated with organizing pneumonia (OP), which could be confused with disease progression.ObjectiveWe aimed to delineate the characteristics of OP that occurs during treatment with ceritinib, and evaluate its clinical implications.Patients and MethodsWe retrospectively analyzed 44 lung cancer patients whose tumors harboredALK orROS1 fusions and who had received ceritinib. OP diagnosis was based on radiographic and clinical features. Four OP cases were pathologically confirmed.ResultsAmong ...
Source: Targeted Oncology - July 14, 2020 Category: Cancer & Oncology Source Type: research

Identifying Prostate Surface Antigen Patterns of Change in Patients with Metastatic Hormone Sensitive Prostate Cancer Treated with Abiraterone and Prednisone
This study investigates the role of prostate surface antigen (PSA) kinetics as a predictor of progression in mHSPC patients treated with AA/P.Patients and MethodsAll patients with mHSPC who initiated androgen deprivation therapy (ADT) and AA/P from June 2017 to February 2019 at the Cleveland Clinic were eligible. PSA-mCRPC was defined as a PSA rise at two consecutive time points. Patients were followed until first mCRPC or last contact after AA/P. Patterns of PSA change were evaluated using a longitudinal mixed model at time 0, 3, 6, 9, and 12  months from AA/P initiation. The association between PSA profile at 3 ...
Source: Targeted Oncology - July 12, 2020 Category: Cancer & Oncology Source Type: research

Clinical Relevance of BRAF V600E Mutation Status in Brain Tumors with a Focus on a Novel Management Algorithm
AbstractThe possible application of BRAF-targeted therapy in brain tumors is growing continuously. We have analyzed clinical strategies that address BRAF activation in primary brain tumors and verified current recommendations regarding screening for BRAF mutations. There is preliminary evidence for a range of positive responses in certain brain tumor types harboring the BRAF V600E mutation. National Comprehensive Cancer Network Guidelines for central nervous system cancers recommend screening for the BRAF V600E mutation in pilocytic astrocytoma, pleomorphic xanthoastrocytoma, and ganglioglioma. We suggest additional testin...
Source: Targeted Oncology - July 8, 2020 Category: Cancer & Oncology Source Type: research

Real-World Outcomes of Pazopanib Treatment in Korean Patients with Advanced Soft Tissue Sarcoma: A Multicenter Retrospective Cohort Study
ConclusionsThis real-world data analysis showed acceptable efficacy and tolerability of pazopanib in patients pretreated with cytotoxic chemotherapy for advanced STS, with favorable treatment outcomes for ASPS and SFT. (Source: Targeted Oncology)
Source: Targeted Oncology - June 29, 2020 Category: Cancer & Oncology Source Type: research

Immune Checkpoint Blockade in Patients with Triple-Negative Breast Cancer
AbstractTriple-negative breast cancer constitutes  ~ 15% of all breast cancer subtypes. Because of the negative hormone receptor and human epidermal growth factor receptor 2 status, therapy is mainly based on chemotherapy with a poor median overall survival in the metastatic setting of ~ 18 months. Compared to other breast cancer subtypes, triple-negative breast cancer is characterized by a higher mutational load, which renders the tumor immunogenic and amenable to immunotherapeutic intervention. Based on the promising results of immunotherapy in other cancer entities, including melanoma or...
Source: Targeted Oncology - June 7, 2020 Category: Cancer & Oncology Source Type: research

Real-World Outcomes in First-Line Treatment of Metastatic Castration-Resistant Prostate Cancer: The Prostate Cancer Registry
ConclusionsThis analysis shows, for the first time, the effectiveness in parallel of first-line abiraterone, enzalutamide, and docetaxel in mCRPC, including in patients with co-morbidities such as cardiovascular disease or diabetes mellitus or in patients with visceral metastases. These real-world findings from the PCR provide meaningful information to help manage mCRPC, particularly in patients under-represented in clinical studies.Trial RegistrationClinicalTrials.gov identifier NCT02236637; registered September 2014. (Source: Targeted Oncology)
Source: Targeted Oncology - June 3, 2020 Category: Cancer & Oncology Source Type: research

Molecular Targeting of a BRAF Mutation in Pancreatic Ductal Adenocarcinoma: Case Report and Literature Review
AbstractCurrent standard-of-care treatment for advanced pancreatic ductal adenocarcinoma is mainly based on conventional cytotoxic chemotherapy. Until recently, no randomized clinical trials had shown any clinically meaningful outcome benefit from targeted therapy in this indication. This is in contrast to many other tumor types. The majority of pancreatic tumors are driven by KRAS mutations, which are generally not amenable to targeted therapy. Driving mutations in the BRAF oncogene have proven to be an interesting molecular target in the management of advanced melanoma and colorectal adenocarcinoma and can be found in 3%...
Source: Targeted Oncology - June 2, 2020 Category: Cancer & Oncology Source Type: research

Management of Adverse Events During Rucaparib Treatment for Relapsed Ovarian Cancer: A Review of Published Studies and Practical Guidance
AbstractThe poly(ADP-ribose) polymerase inhibitor rucaparib is approved as monotherapy in the treatment and maintenance settings for women with relapsed ovarian cancer in the European Union and the United States. We review the safety profile of rucaparib in both settings and provide recommendations for the clinical management of the main adverse events (AEs) that may occur during rucaparib treatment. We searched PubMed and congress proceedings for safety data on oral rucaparib monotherapy (600  mg twice daily) from clinical trials involving patients with relapsed ovarian cancer. AE management guidance was developed fr...
Source: Targeted Oncology - June 2, 2020 Category: Cancer & Oncology Source Type: research

Targeting CD79b for Chimeric Antigen Receptor T-Cell Therapy of B-Cell Lymphomas
ConclusionsOur data indicate that CD79b could be used as a target for CAR T-cell therapy of B-cell lymphomas, and further clinical development is warranted. (Source: Targeted Oncology)
Source: Targeted Oncology - June 2, 2020 Category: Cancer & Oncology Source Type: research

Clinical Factors Affecting the Response to Osimertinib in Non-Small Cell Lung Cancer Patients with An Acquired Epidermal Growth Factor Receptor T790M Mutation: A Long-Term Survival Analysis
ConclusionsThis is the first reported survival analysis of osimertinib-treated Chinese patients, which indicates a median OS of 47.86  months. The EGFR T790M mutation is likely to coexist with 19del and indicate longer PFS and OS1 than EGFR 21 L858R/T790M. Additionally, the extrathoracic metastasis status and biopsy specimen type might also affect the survival of patients treated with osimertinib. (Source: Targeted Oncology)
Source: Targeted Oncology - June 2, 2020 Category: Cancer & Oncology Source Type: research